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Background 
• Several studies investigated trends in behavioral health 
medication use in youth.  
- Increase in behavioral health medication polypharmacy 
regimens 
- Increase in utilization of antipsychotic agents in pediatric 
patients and in combination with other behavioral health 
medications 
 
• U.S. Government Accountability Office reported concerns 
with behavioral health medications prescribed in children. 
- December 2011 Report: Highest rate of utilization in MA 
compared to other states (FL, MI, OR, TX) 
- December 2012 Report: Behavioral health regimens 
with ≥5 medications more prevalent in foster care 
children 
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Response to Pediatric Behavioral 
Health Medication  Concerns 
• MassHealth Pharmacy Program developed the PBHMI 
- Department of Children and Families (DCF)  
- Department of Mental Health (DMH) 
 
• Prospective Prior Authorization (PA) requirement 
- Members less than 18 years of age 
- Behavioral health medication combinations (i.e., 
polypharmacy) 
- Medication classes with limited evidence of safety and 
efficacy in the pediatric population 
 
• MassHealth PBHMI guideline criteria 
- Evidence-based medicine 
- DMH Expert Workgroup Advisory Board 
 
*Lookback period for behavioral health medication polypharmacy was changed from 60 days to 45 days on 6/1/2015. 
PBHMI PA Requirements 
PA requirements for member <3 years old (effective 11/24/14) 
Any pharmacy claim for an alpha2 agonist or cerebral stimulant 
PA requirements for members <6 years old (effective 11/24/14) 
Any pharmacy claim for an antipsychotic, antidepressant, atomoxetine, benzodiazepine, 
buspirone, hypnotic, or mood stabilizer 
PA requirements for members <18 years old (effective 2/23/15) 
Type of polypharmacy Number of medications and duration 
Antidepressant 2 or more ≥60 days within a 90 day period 
Antipsychotic 2 or more ≥60 days within a 90 day period 
Benzodiazepine 2 or more ≥60 days within a 90 day period 
Cerebral Stimulant 2 or more ≥60 days within a 90 day period 
Mood Stabilizer 3 or more ≥60 days within a 90 day period 
Behavioral Health Medication 4 or more within a 45 day period* 
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PBHMI Timeline 
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Prescriber  
Letter Mailings 
(N=14,352) 
• Prescribers  
for members  
<18 years old 
• Massachusetts  
and border states 
Age Restrictions  
          (N=79) 
• Prescribers for 
behavioral health 
medications for  
≥5 members  
<6 years old 
• Prescribers  
for members  
<3 years old 
 
   Polypharmacy     
     Restrictions 
         (N=239) 
• Prescribers  
of behavioral  
health medication 
polypharmacy  
for ≥7 members  
<18 years old 
Telephonic Prescriber Outreach 
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Outreach Efforts Prior to Implementation 
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Organizations 
• Department of  
Mental Health (DMH) 
• Department of 
Children and  
Families (DCF) 
• Department of Youth 
Services (DYS) 
• Advocacy groups 
MassHealth  
Drug List webpage 
• Clinical document 
• Therapeutic class 
tables, criteria, prior 
authorization forms 
• Frequently asked 
questions 
Electronic 
Communication 
• MassHealth  
E-prescriber Letter 
(N=280 prescribers) 
• Pharmacy Facts 
(N=1,100 
pharmacies) 
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Outreach Efforts Prior to Implementation 
* Initial duration of approval was changed from six months to one year on 3/10/2015. 
† Provisional approvals include three month approval durations for recent hospitalization or documented harm to self or others. 
‡ Other behavioral health classes include medications that require PA for the agent, formulation, or quantity limits  
   (e.g., ADHD, alpha2 agonists, antianxiety, anticonvulsants, antidepressants, antipsychotics).  
Time Period: 11/24/14 to 11/30/15 
Unique Utilizers: 3,399 
Total PBHMI PAs  
18,478 
Approvals*  
12,723 
PBHMI  
11,640 
Other 
Behavioral 
Health 
Classes‡ 
1,083 
Provisional Approvals† 
5,521 
PBHMI 
5,194 
Other 
Behavioral 
Health 
Classes‡ 
327 
Denials  
234 
PBHMI  
116 
Other 
Behavioral 
Health 
Classes‡  
118 
8 
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PBHMI PA Volume 
Total PBHMI PAs 
18,478 
PBHMI PA Category  
16,950 
Age <3 
23 
Age <6 
759 
Polypharmacy‡ 
1,281 
Multiple Behavioral 
Health Medications§ 
14,887 
Other Behavioral Health Categories† 
1,528 
* PA category/status reason may include multiple reasons (e.g., age, polypharmacy, multiple behavioral health medications). 
† Other behavioral health classes include medications that require PA for the agent, formulation, or quantity limits  
   (e.g., ADHD, alpha2 agonists, antianxiety, anticonvulsants, antidepressants, antipsychotics). 
‡ Polypharmacy includes the use of two  or more agents in the same behavioral health medication class  
(e.g.,≥ 2 antipsychotics, ≥ 3 mood stabilizers ). 
§ Multiple behavioral health medications include regimens with ≥4 behavioral health medications.  
Time Period: 11/24/14 to 11/30/15 
Unique Utilizers: 3,399 
9 
PBHMI PA Volume by Category*  
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Recent Updates 
 
• In August 2016 MassHealth implemented changes to PBHMI 
antipsychotic polypharmacy restrictions and antipsychotic age 
restrictions 
- Clinical Criteria Updates  
 Evaluation of complete treatment plan, comprehensive 
behavioral health plan, prescriber speciality, stage of 
therapy and clinical rationale for extended therapy (as 
applicable) 
- PBHMI TCM Workgroup Intervention 
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Therapeutic Class Management  
(TCM) Workgroup 
• Multidisciplinary team 
- Child Adolescent Psychiatrists 
 Steven Feldman, MD 
 Joel Goldstein, MD 
- Clinical pharmacists 
 Michael Angelini, M.A., PharmD, BCPP 
 Neha Kashalikar, PharmD 
 Kimberly Lenz, PharmD 
 Patricia Leto, PharmD 
 Mylissa Price, MPH, RPh 
 Mark Tesell, PharmD, BCPS 
- Social worker 
- Lee-Anne Jacobs, LICSW 
September 2016 
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Therapeutic Class Management  
(TCM) Workgroup 
• Responsibilities 
- Clinical discussions regarding treatment plans 
- Prescriber outreach to encourage evidence-based 
prescribing practices 
- Referral of members to the Massachusetts Behavioral Health 
Partnership (MBHP)  
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• Member cases evaluated 
– Regimens with ≥6 behavioral health medications 
– Recent psychiatric hospitalization 
– Members <3 years of age  
– Antipsychotic age <6 years of age* 
– Antipsychotic polypharmacy* 
 
 
Cases Escalated for TCM Workgroup 
Intervention 
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* Cases forwarded for PBHMI TCM Workgroup review as of 08/29/2016  
TCM Workgroup Workflow for Case Evaluation 
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PA request 
reviewed  
by pharmacist 
Case forwarded  
to the TCM 
Workgroup if  
it meets TCM 
criteria 
TCM Workgroup  
reviews daily cases and 
determines which will  
be discussed during 
weekly meeting 
Cases discussed during 
weekly TCM meeting 
Interventions include prescriber outreach, 
referral to the Massachusetts Behavioral Health 
Partnership (MBHP), or further evaluation upon 
resubmission or regimen change 
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• 15 y/o female with PTSD, bipolar disorder, anxiety, MDD, RLS, and 
self-injury 
• Medication regimen:  
– quetiapine 800 mg HS 
– risperidone 0.5 mg BID 
– lithium 600 mg BID 
– haloperidol 5 mg every 4 hours as needed  
– fluoxetine 30 mg QD 
– gabapentin 900 mg QD &  600 mg as needed  
– topiramate 25 mg QHS 
 
 
Abbreviations: BID=twice daily, HS= at bedtime, MDD=Major Depressive Disorder, PTSD=Post-traumatic Stress Disorder, 
QAM=every morning, QD=daily, QHS=every night at bedtime, RLS=Restless Leg Syndrome, y/o=year old  
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Sample TCM Case 
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• Prescriber outreach conducted to discuss opportunities for regimen 
simplification. 
• Subsequent medication regimen:  
– ziprasidone 80 mg BID 
– haloperidol 5 mg every 4 hours as needed  
– sertraline 100 mg QD 
– gabapentin 900 mg QD &  600 mg as needed  
– trazodone 50 mg QHS 
 
 
Abbreviations: BID=twice daily, QD=daily, QHS=every night at bedtime 
TCM Case Follow-up 
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PBHMI Resources 
• MassHealth Drug List Webpage 
- Clinical Document 
- Therapeutic Class Tables and Criteria 
- Prior Authorization Forms 
- Frequently Asked Questions 
 
• DUR Clinical Call Center (800-745-7318) 
- Prescribers and pharmacies only 
- Status of prior authorizations, claim adjudication, overrides, 
and emergency supplies 
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Successes 
• Cross-agency collaboration 
– Vetting of approval criteria and PA process through psychiatry experts  
in the field 
– Stakeholder meetings prior to  and throughout implementation  
(e.g., DCF, DMH, Executive Office of Health and Human Services) 
• Development of a multidisciplinary team 
– Clinical expert consensus on criteria and complex cases 
– Weekly operations meeting to discuss criteria updates, computer  
coding, PA volume, and prescriber/pharmacy feedback  
– Weekly TCM workgroup meetings to evaluate concerning cases  
with prescriber outreach to discuss treatment plan and options 
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Challenges 
• Coordinating care in a complex system 
– Multiple prescribers with different specialties 
 Communication  
– Post discharge follow-up 
 Medication reconciliation 
 Frequent relapses 
– Alternative sites of care 
 Residential treatment facilities 
 Partial hospitalization  programs (outpatient based) 
– Behavioral health services ≠ coordinated care 
 Many services offered or received but may not be 
integrated 
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Summary 
• PBHMI will continue to expand and identify areas for improvement. 
 
• Prescriber outreach and additional resources are available to assist 
in not disrupting member care. 
 
• The TCM workgroup will continue to evaluate clinically complex 
cases and encourage safe prescribing practices. 
 
• PBHMI prior authorization requests will continue to be monitored on 
through quality assurance analyses. 
 
• PBHMI will continually be evaluated and criteria will be adjusted as 
needed based on current evidence-based medicine. 
 
September 2016 
Questions? 
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